Scarica l'app Stockscreener
4.61
0.66%
0.03
Dopo l'orario di chiusura:
4.61
Precedente Chiudi:
$4.58
Aprire:
$4.51
Volume 24 ore:
982.52K
Relative Volume:
1.17
Capitalizzazione di mercato:
$473.93M
Reddito:
$380.79M
Utile/perdita netta:
$49.27M
Rapporto P/E:
6.5857
EPS:
0.7
Flusso di cassa netto:
$10.68M
1 W Prestazione:
-13.35%
1M Prestazione:
+32.09%
6M Prestazione:
-31.19%
1 anno Prestazione:
+143.92%
Intervallo 1D:
$4.405
$4.82
Intervallo di 1 settimana:
$4.405
$5.36
Portata 52W:
$1.575
$7.27
Amylyx Pharmaceuticals Inc Stock (AMLX) Company Profile
Nome
Amylyx Pharmaceuticals Inc
Settore
Industria
Telefono
617-683-0917
Indirizzo
43 THORNDIKE STREET, CAMBRIDGE
Confronta AMLX con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
AMLX
Amylyx Pharmaceuticals Inc
|
4.61 | 473.93M | 380.79M | 49.27M | 10.68M | 0.70 |
|
VRTX
Vertex Pharmaceuticals Inc
|
424.99 | 128.84B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
527.78 | 65.38B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
549.65 | 39.67B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
251.15 | 33.82B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ONC
Beigene Ltd Adr
|
231.99 | 27.60B | 3.81B | -644.79M | -669.77M | -6.24 |
Amylyx Pharmaceuticals Inc Stock (AMLX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-04-07 | Aggiornamento | Mizuho | Neutral → Outperform |
| 2024-11-18 | Aggiornamento | Robert W. Baird | Neutral → Outperform |
| 2024-10-23 | Aggiornamento | BofA Securities | Neutral → Buy |
| 2024-03-18 | Downgrade | Mizuho | Buy → Neutral |
| 2024-03-11 | Downgrade | Leerink Partners | Outperform → Market Perform |
| 2024-03-11 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2024-03-08 | Downgrade | Evercore ISI | Outperform → In-line |
| 2024-03-08 | Downgrade | Goldman | Buy → Neutral |
| 2024-01-03 | Iniziato | Robert W. Baird | Outperform |
| 2023-12-12 | Iniziato | Deutsche Bank | Buy |
| 2023-07-24 | Aggiornamento | Goldman | Neutral → Buy |
| 2023-03-31 | Iniziato | Mizuho | Buy |
| 2023-01-05 | Iniziato | BofA Securities | Buy |
| 2022-05-25 | Iniziato | Citigroup | Buy |
| 2022-04-01 | Downgrade | Goldman | Buy → Neutral |
Mostra tutto
Amylyx Pharmaceuticals Inc Borsa (AMLX) Ultime notizie
Amylyx Pharmaceuticals, Inc. 2025 Q1ResultsEarnings Call Presentation (NASDAQ:AMLX) - Seeking Alpha
Here's Why We're A Bit Worried About Amylyx Pharmaceuticals' (NASDAQ:AMLX) Cash Burn Situation - Yahoo Finance
Shareholders of Amylyx Pharmaceuticals, Inc. Should Contact Levi & Korsinsky Before April 9, 2024 to Discuss Your Rights – AMLX - ACCESS Newswire
Amylyx Pharmaceuticals (AMLX) Target Price Raised by HC Wainwrig - GuruFocus
Amylyx Pharmaceuticals (NASDAQ:AMLX) Upgraded at Leerink Partnrs - Defense World
Amylyx Pharmaceuticals Reports First Quarter 2025 Financial Results - BioSpace
Amylyx Pharmaceuticals (NASDAQ:AMLX) Stock Rating Upgraded by Leerink Partners - Defense World
Amylyx Pharmaceuticals Advances Clinical Trials and Strengthens Finances - TipRanks
Amylyx Pharmaceuticals Q1 2025 Earnings Call Transcript - MarketBeat
Investors in Amylyx Pharmaceuticals, Inc. Should Contact Levi & Korsinsky Before April 9, 2024 to Discuss Your RightsAMLX - ACCESS Newswire
Class Action Filed Against Amylyx Pharmaceuticals, Inc. (AMLX)April 9, 2024 Deadline to JoinContact Levi & Korsinsky - ACCESS Newswire
Mariner LLC Decreases Position in Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) - Defense World
Amylyx Pharmaceuticals Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Transcript : Amylyx Pharmaceuticals, Inc., Q1 2025 Earnings Call, May 08, 2025 - marketscreener.com
Amylyx Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025 - marketscreener.com
This Biotech Found Mid-Week Success Following Analyst Upgrade - The Globe and Mail
Amylyx Pharmaceuticals Shares Rise After Upgrade From Leerink - marketscreener.com
Amylyx Pharmaceuticals (AMLX) Rating Upgraded by Leerink Partner - GuruFocus
Amylyx Pharmaceuticals to Participate in Upcoming May Investor Conferences - BioSpace
Lumentum Holdings To Rally Around 46%? Here Are 10 Top Analyst Forecasts For Wednesday - Benzinga
Leerink Partners Upgrades Amylyx Pharmaceuticals (AMLX) - Nasdaq
This Logitech International Analyst Turns Bullish; Here Are Top 4 Upgrades For Wednesday - Benzinga
Tower Research Capital LLC TRC Has $174,000 Holdings in Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) - Defense World
Amylyx Pharmaceuticals (AMLX) Projected to Post Earnings on Thursday - Defense World
Amylyx (AMLX) Upgraded as Avexitide Gains Momentum | AMLX Stock News - GuruFocus
Bronstein, Gewirtz & Grossman, LLC Is Investigating Amylyx Pharmaceuticals, Inc. (AMLX) And Encourages Shareholders to Connect - ACCESS Newswire
Amylyx Pharmaceuticals, Inc. Sued for Securities Law ViolationsInvestors Should Contact Levi & Korsinsky for More InformationAMLX - ACCESS Newswire
Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Shares Sold by JPMorgan Chase & Co. - Defense World
UPCOMING AMLX DEADLINE: Bronstein, Gewirtz & Grossman LLC Reminds Amylyx Pharmaceuticals, Inc. Investors to Join the Class Action Lawsuit! - ACCESS Newswire
This trade activity should not be overlooked: Amylyx Pharmaceuticals Inc (AMLX) - Sete News
Press Release Distribution & PR Platform - ACCESS Newswire
Amylyx Pharmaceuticals to Report First Quarter 2025 Financial Results on May 8, 2025 - BioSpace
Investor’s Delight: Amylyx Pharmaceuticals Inc (AMLX) Closes Strong at 5.11, Up 4.29 - DWinneX
Amylyx doses first subject in trial of post-bariatric hypoglycaemia treatment - Yahoo Finance
Amylyx (AMLX) Begins Phase 3 Trial for Post-Bariatric Hypoglycem - GuruFocus
Potential Price Increase for Amylyx Pharmaceuticals Inc (AMLX) After Recent Insider Activity - knoxdaily.com
Amylyx Pharmaceuticals Starts Dosing in Phase 3 Trial for Post-Bariatric Hypoglycemia Treatment - marketscreener.com
Amylyx Pharmaceuticals Inc (AMLX) stock: A year of ups and downs - uspostnews.com
Amylyx (AMLX) Begins Phase 3 Trial for Post-Bariatric Hypoglycemia Treatment | AMLX Stock News - GuruFocus
Amylyx Pharmaceuticals Announces First Participant Dosed in Pivotal Phase 3 LUCIDITY Trial of Avexitide in Post-Bariatric Hypoglycemia - BioSpace
Amylyx starts Phase 3 trial for hypoglycemia treatment By Investing.com - Investing.com India
Amylyx starts Phase 3 trial for hypoglycemia treatment - Investing.com
Amylyx Pharmaceuticals Announces First Participant Dosed In Pivotal Phase 3 Lucidity Trial Of Avexitide In Post-Bariatric Hypoglycemia - marketscreener.com
Guggenheim Capital LLC Has $136,000 Stock Holdings in Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) - Defense World
Geode Capital Management LLC Grows Position in Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) - Defense World
AMLX’s Stock Journey: What Investors Need to Know About Amylyx Pharmaceuticals Inc’s Performance - investchronicle.com
Amylyx Pharma Gearing Up For FDA Decision - RTTNews
Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Receives Average Rating of “Moderate Buy” from Brokerages - Defense World
Amylyx Pharmaceuticals Inc Azioni (AMLX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.84%
0.15%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):